samedan logo
home > pmps > autumn 2021 > the prescription for pharma’s digital future
Pharmaceutical Manufacturing and Packing Sourcer

The Prescription for Pharma’s Digital Future

Before the COVID-19 pandemic unfolded, the global pharmaceutical sector had shown interest in artificial intelligence (AI) and automation, but had yet to embrace it as wholeheartedly as other industries.

Some analysts put the slow adoption down to the highly regulated nature of the industry, others to the lead times involved in the discovery and commercialisation process.

Pharma is a sector with development cycles measured in years, if not decades. The costs of developing new medicines run into the billions, and the success rate for an approved treatment is around one in ten. Rightly or wrongly, many pharma executives questioned the return on investment in a technology viewed as esoteric and unproven.

However, fast forward just 18 months, and one global pandemic, and that mindset could be shifting. According to a report earlier this year from data analytics and consulting company, GlobalData, AI was the top Industry 4.0 technology pharma companies were interested in. More than one in three pharma executives predicted it to have the largest impact on their sector, closely followed by Big Data (20%) (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Andrew Borland is Head of Commercial of the University of Liverpool’s Virtual Engineering Centre. He leads the new Cheshire and Warrington 4.0 programme offering SME pharma manufacturers in Cheshire and Warrington fully funded, hands-on support with industrial technologies, through the European Regional Development Fund.

Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement